Vor Biopharma Inc.
VOR
Rank in Stocks
#8340
Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to... Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer. Its lead product candidate, VOR33, is an eHSC therapy currently undergoing Phase 1/2 clinical trials. VOR33 is designed to target acute myeloid leukemia (AML) and various other hematological malignancies. A key feature of VOR33's eHSCs is their engineered absence of the CD33 protein, which is commonly found on AML blood cancer cells. The company's eHSC platform is intended to enable a range of targeted blood cancer treatments, including CAR-T cell therapies, bispecific antibodies, and antibody-drug conjugates. Vor Biopharma has established a partnership with Akron BioProducts for the development and manufacturing of cGMP nucleases. Established in 2015, the company's headquarters are located in Cambridge, Massachusetts.
Share Price
$19.98
Last synced: 2026-11-09
Market Cap
$1.08B
Change (1 day)
0.50%
Change (1 year)
103.05%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade Vor Biopharma Inc. (VOR)
Category
Healthcare
EPS for Vor Biopharma Inc. (VOR)
EPS as of September 2026 TTM: $299.81
According to Vor Biopharma Inc.'s latest financial reports, its current EPS (TTM) is $299.81. At the end of 2025 the company had an EPS of $-70.50, a decrease compared to its 2024 EPS of $-34.00.
EPS history for Vor Biopharma Inc. from 2018 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $299.81 | -525.26% |
| 2025 | $-70.50 | 107.35% |
| 2024 | $-34.00 | -2.86% |
| 2023 | $-35.00 | -24.89% |
| 2022 | $-46.60 | 23.28% |
| 2021 | $-37.80 | 42.11% |
| 2020 | $-26.60 | 329.03% |
| 2019 | $-6.20 | -57.53% |
| 2018 | $-14.60 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -94.78% |
US
|
|
| $-7.07 | -102.36% |
US
|
|
| $-5.29 | -101.76% |
AU
|
|
| $12.88 | -95.70% |
BE
|
|
| $21.56 | -92.81% |
NL
|
Questions about Vor Biopharma Inc.'s earnings per share (EPS)
What is Vor Biopharma Inc.'s earnings per share (EPS)?
Vor Biopharma Inc.'s earnings per share (EPS) over the last twelve months is $299.81, as of Sep 2026.
What was Vor Biopharma Inc.'s earnings per share (EPS) in 2025?
In 2025, Vor Biopharma Inc.'s earnings per share (EPS) was $-70.50, compared with $-34.00 in 2024.
How has Vor Biopharma Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Vor Biopharma Inc.'s earnings per share (EPS) was highest in 2020 ($-26.60) and lowest in 2025 ($-70.50).
How does Vor Biopharma Inc.'s earnings per share (EPS) compare with similar companies?
Vor Biopharma Inc.'s earnings per share (EPS) ($299.81) is higher than that of all 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.